

Paul A Sobotka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11966490/publications.pdf>

Version: 2024-02-01

83
papers

13,602
citations

66250

44
h-index

73587

79
g-index

83
all docs

83
docs citations

83
times ranked

5924
citing authors

#	ARTICLE	IF	CITATIONS
1	Extracardiac Abnormalities of Preload Reserve. <i>Circulation: Heart Failure</i> , 2021, 14, e007308.	1.6	33
2	Renal Denervation for Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008301.	1.6	10
3	Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. <i>European Journal of Heart Failure</i> , 2021, 23, 1076-1084.	2.9	37
4	Correlation of Quantitated Intravascular Volume with Blood Pressure in Patients with Systemic Hypertension. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 528-530.	1.1	4
5	Sham trials: benefits and risks for cardiovascular research and patients. <i>Lancet, The</i> , 2019, 393, 2104-2106.	6.3	7
6	Selective vs. Global Renal Denervation: a Case for Less Is More. <i>Current Hypertension Reports</i> , 2018, 20, 37.	1.5	27
7	Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 18.	1.5	5
8	Central arteriovenous anastomosis to treat resistant hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 8-15.	1.0	10
9	Catheter-Based Renal Denervation for Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 93.	1.5	16
10	Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea. <i>Hypertension</i> , 2018, 72, 381-390.	1.3	73
11	Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE-HF extended trial. <i>ESC Heart Failure</i> , 2018, 5, 788-799.	1.4	23
12	Interventional procedures and future drug therapy for hypertension. <i>European Heart Journal</i> , 2017, 38, ehw303.	1.0	34
13	Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension. <i>Hypertension</i> , 2017, 70, 1099-1105.	1.3	44
14	Carotid body resection for sympathetic modulation in systolic heart failure: results from first-in-man study. <i>European Journal of Heart Failure</i> , 2017, 19, 391-400.	2.9	97
15	Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	22
16	Unilateral Carotid Body Resection in Resistant Hypertension. <i>JACC Basic To Translational Science</i> , 2016, 1, 313-324.	1.9	118
17	Antihypertensive Effects of a Central Arteriovenous Anastomosis Are Mediated Through Profound Reduction in Systemic Vascular Resistance. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e004012.	1.4	10
18	Central arteriovenous anastomosis and hypertension – Authors' reply. <i>Lancet, The</i> , 2015, 386, 1821-1822.	6.3	1

#	ARTICLE	IF	CITATIONS
19	Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. <i>Lancet, The</i> , 2015, 385, 1634-1641.	6.3	155
20	The ROX coupler: Creation of a fixed iliac arteriovenous anastomosis for the treatment of uncontrolled systemic arterial hypertension, exploiting the physical properties of the arterial vasculature. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 880-886.	0.7	28
21	Central Iliac Arteriovenous Anastomosis for Hypertension: Targeting Mechanical Aspects of the Circulation. <i>Current Hypertension Reports</i> , 2015, 17, 585.	1.5	23
22	Predictors of blood pressure response in the SYMPPLICITY HTN-3 trial. <i>European Heart Journal</i> , 2015, 36, 219-227.	1.0	458
23	The Endpoint on Measuring the Clinical Effects of Renal Denervation: What Are the Best Surrogates. , 2015, , 25-43.		0
24	Response to Letter Regarding Article, "Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension". <i>Circulation</i> , 2014, 129, e500-1.	1.6	0
25	The Thrill of Success: Central Arterial-Venous Anastomosis for Hypertension. <i>Current Hypertension Reports</i> , 2014, 16, 497.	1.5	2
26	Dissociation between blood pressure and heart rate response to hypoxia after bilateral carotid body removal in men with systolic heart failure. <i>Experimental Physiology</i> , 2014, 99, 552-561.	0.9	52
27	Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. <i>Lancet, The</i> , 2014, 383, 622-629.	6.3	556
28	Meta-Analysis of the Effect of Renal Denervation on Blood Pressure and Pulse Pressure in Patients With Resistant Systemic Hypertension. <i>American Journal of Cardiology</i> , 2014, 114, 856-861.	0.7	21
29	Arteriovenous Anastomosis. <i>Hypertension</i> , 2014, 64, 6-12.	1.3	49
30	Chemohypersensitivity and Autonomic Modulation of Venous Capacitance in the Pathophysiology of Acute Decompensated Heart Failure. <i>Current Heart Failure Reports</i> , 2013, 10, 139-146.	1.3	24
31	Revelations About Carotid Body Function Through its Pathological Role in Resistant Hypertension. <i>Current Hypertension Reports</i> , 2013, 15, 273-280.	1.5	62
32	Does Renal Artery Supply Indicate Treatment Success of Renal Denervation?. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 987-991.	0.9	7
33	Response to Role of the Carotid Body in Obesity-Related Sympathoactivation. <i>Hypertension</i> , 2013, 61, e58.	1.3	2
34	The Carotid Body as a Therapeutic Target for the Treatment of Sympathetically Mediated Diseases. <i>Hypertension</i> , 2013, 61, 5-13.	1.3	232
35	International Expert Consensus Statement. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2031-2045.	1.2	124
36	First-in-man safety evaluation of renal denervation for chronic systolic heart failure: Primary outcome from REACH-Pilot study. <i>International Journal of Cardiology</i> , 2013, 162, 189-192.	0.8	274

#	ARTICLE	IF	CITATIONS
37	The carotid body as a putative therapeutic target for the treatment of neurogenic hypertension. <i>Nature Communications</i> , 2013, 4, 2395.	5.8	204
38	Ready for a Marathon, Not a Sprint. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2131-2133.	1.2	7
39	Renal Denervation in Moderate Treatment-Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1880-1886.	1.2	93
40	Fluid Re-Distribution Rather Than Accumulation Causes Most Cases of Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 165-166.	1.2	22
41	Carotid body removal for treatment of chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 2506-2509.	0.8	83
42	Clinical Predictors and Hemodynamic Consequences of Elevated Peripheral Chemosensitivity in Optimally Treated Men With Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 408-415.	0.7	43
43	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , 2013, 168, 2214-2220.	0.8	122
44	Renal nerve ablation reduces augmentation index in patients with resistant hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1893-1900.	0.3	66
45	Vascular and Renal Hemodynamic Changes after Renal Denervation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1195-1201.	2.2	51
46	Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension. <i>Circulation</i> , 2013, 128, 132-140.	1.6	240
47	Devices for Hypertension. , 2013, , 230-235.		0
48	Renal Denervation in Moderate to Severe CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1250-1257.	3.0	322
49	Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension. <i>Circulation</i> , 2012, 126, 2976-2982.	1.6	420
50	Renal Denervation in a Hypertensive Patient With End-Stage Renal Disease and Small Arteries: A Direction for Future Research. <i>Journal of Clinical Hypertension</i> , 2012, 14, 799-801.	1.0	35
51	Efficiently Doing the Wrong Thing. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1713.	1.2	1
52	Renal Denervation for Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 249-258.	1.1	70
53	Catheter-Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPPLICITY HTN-3 Trial. <i>Clinical Cardiology</i> , 2012, 35, 528-535.	0.7	278
54	The Role of Renal Denervation in the Treatment of Heart Failure. <i>Current Cardiology Reports</i> , 2012, 14, 285-292.	1.3	83

#	ARTICLE	IF	CITATIONS
55	Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects. <i>Current Hypertension Reports</i> , 2012, 14, 247-253.	1.5	43
56	Hypertension is critically dependent on the carotid body input in the spontaneously hypertensive rat. <i>Journal of Physiology</i> , 2012, 590, 4269-4277.	1.3	188
57	Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. <i>Clinical Research in Cardiology</i> , 2012, 101, 63-67.	1.5	216
58	Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension. <i>Circulation</i> , 2011, 123, 1940-1946.	1.6	541
59	Renal Denervation and Hypertension. <i>American Journal of Hypertension</i> , 2011, 24, 635-642.	1.0	63
60	Cardiorespiratory Response to Exercise After Renal Sympathetic Denervation in Patients With Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1176-1182.	1.2	142
61	Recent advances in the treatment of hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 729-744.	0.6	14
62	Renal denervation: a potential new treatment modality for polycystic ovary syndrome?. <i>Journal of Hypertension</i> , 2011, 29, 991-996.	0.3	124
63	Sympatho-renal axis in chronic disease. <i>Clinical Research in Cardiology</i> , 2011, 100, 1049-1057.	1.5	155
64	Response to Letter Regarding Article, "Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study". <i>Circulation</i> , 2011, 124, .	1.6	0
65	Sympathetically Mediated Changes in Capacitance. <i>Circulation: Heart Failure</i> , 2011, 4, 669-675.	1.6	251
66	Effects of Renal Sympathetic Denervation on Blood Pressure, Sleep Apnea Course, and Glycemic Control in Patients With Resistant Hypertension and Sleep Apnea. <i>Hypertension</i> , 2011, 58, 559-565.	1.3	427
67	Renal Sympathetic Nerve Ablation: The New Frontier in the Treatment of Hypertension. <i>Current Hypertension Reports</i> , 2010, 12, 39-46.	1.5	41
68	Renal Nerves in the Maintenance of Hypertension: A Potential Therapeutic Target. <i>Current Hypertension Reports</i> , 2010, 12, 196-204.	1.5	23
69	Ultrafiltration is Associated With Fewer Rehospitalizations than Continuous Diuretic Infusion in Patients With Decompensated Heart Failure: Results From UNLOAD. <i>Journal of Cardiac Failure</i> , 2010, 16, 277-284.	0.7	130
70	The Sympathorenal Axis in Hypertension and Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, 369-373.	0.7	23
71	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2) Tj ETQq1 1 0.784314 rgBT /Ov 6.3 2,002	1.0	2,002
72	Loop Diuretics Can Cause Clinical Natriuretic Failure: A Prescription for Volume Expansion. <i>Congestive Heart Failure</i> , 2009, 15, 1-4.	2.0	63

#	ARTICLE	IF	CITATIONS
73	Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension. <i>New England Journal of Medicine</i> , 2009, 361, 932-934.	13.9	702
74	Renal Denervation as a Therapeutic Approach for Hypertension. <i>Hypertension</i> , 2009, 54, 1195-1201.	1.3	220
75	Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. <i>Lancet, The</i> , 2009, 373, 1275-1281.	6.3	1,918
76	A Practical Guide for Ultrafiltration in Acute Decompensated Heart Failure. <i>Congestive Heart Failure</i> , 2008, 14, 83-88.	2.0	14
77	The Improved Outcomes Following Ultrafiltration Versus Intravenous Diuretics in UNLOAD Are Not Solely Due to Increased Weight Loss in the Ultrafiltration Group. <i>Journal of Cardiac Failure</i> , 2007, 13, S188-S189.	0.7	4
78	Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 675-683.	1.2	978
79	Myocellular and Interstitial Edema and Circulating Volume Expansion as a Cause of Morbidity and Mortality in Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, 133-136.	0.7	37
80	Enhanced Sodium Extraction with Ultrafiltration Compared to Intravenous Diuretics. <i>Journal of Cardiac Failure</i> , 2006, 12, S114.	0.7	14
81	Ultrafiltration Versus Usual Care for Hospitalized Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2005, 46, 2043-2046.	1.2	375
82	Breath pentane and plasma lipid peroxides in ischemic heart disease. <i>Free Radical Biology and Medicine</i> , 1995, 19, 679-684.	1.3	46
83	Expired Hydrocarbons in Patients with Acute Myocardial Infarction. <i>Free Radical Research</i> , 1995, 23, 117-122.	1.5	68